| Medical Policy | Revision |
|---|---|
| Testing for Targeted Therapy of Non-Small-Cell Lung Cancer AHS - M2030 | Reviewed by Avalon Q3 2025 CAB. Medical Director review 9/2025. Updated policy guidelines, guidelines and recommendations and references. Updated Note 1. Under Billing/Coding section: added CPT codes 81445, 81449, 81455, 81456, 0288U and deleted CPT 88342. Under “When Covered” section: clarified coverage statement and removed individual mutations listed. See Note 1 for mutations. Under “When Not Covered” section: added “single gene analysis for genetic alterations and broad molecular profiling panels that do not include the minimum genetic variants found in Note 1” are considered not medically necessary. Notification given 10/15/25 for effective date 12/31/25. |
Blue Cross and Blue Shield of North Carolina does not discriminate on the basis of race, color, national origin, sex, age or disability in its health programs and activities. Learn more about our non-discrimination policy and no-cost services available to you.
Information in other languages: Español 中文 Tiếng Việt 한국어 Français العَرَبِيَّة Hmoob ру́сский Tagalog ગુજરાતી ភាសាខ្មែរ Deutsch हिन्दी ລາວ 日本語
© 2025 Blue Cross and Blue Shield of North Carolina. ®, SM Marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield plans. All other marks and names are property of their respective owners. Blue Cross and Blue Shield of North Carolina is an independent licensee of the Blue Cross and Blue Shield Association.